10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

Impact · against what's priced in

The article provides no catalysts for ARGX as the reported revenue growth and analyst optimism are already factored into the current valuation. The mentioned sales figures and price targets align with existing market expectations and analyst ranges.

ARGX+0.00: Already priced in
The price assumes: The current Vyvgart franchise in generalized myasthenia gravis (gMG)

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

What matters in this story

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

What matters in this story

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

How each ticker is affected

Track these names every morning.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

IG Group shares extend losses as Panmure cuts target price but keeps 'buy'

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

What matters in this story

Next reads from the same story arc

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

What matters in this story

Next reads from the same story arc

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

How each ticker is affected

Track these names every morning.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

IG Group shares extend losses as Panmure cuts target price but keeps 'buy'

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit